British journal of haematology · 2021
Expression of the novel tumour suppressor sterile alpha motif and HD domain-containing protein 1 is an independent adverse prognostic factor in classical Hodgkin lymphoma.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xagoraris Ioanna, Vassilakopoulos Theodoros P, Drakos Elias, Angelopoulou Maria K, Panitsas Fotios, Herold Nikolas, Medeiros L Jeffrey, Giakoumis Xanthoula, Pangalis Gerassimos A, Rassidakis George Z
Аннотация
The expression patterns and prognostic significance of sterile alpha motif and HD domain-containing protein 1 (SAMHD1) protein in the neoplastic Hodgkin and Reed Sternberg (HRS) cells of Hodgkin lymphoma (HL) were investigated in a cohort of 154 patients with HL treated with standard regimens. SAMHD1 expression was assessed by immunohistochemistry using diagnostic lymph node biopsies obtained prior to treatment. Using an arbitrary 20% cut-off, SAMHD1 was positive in HRS cells of 48/154 (31·2%) patients. SAMHD1 expression was not associated with clinicopathologic parameters, such as age, gender, stage or histologic subtype. In 125 patients with a median follow-up of 90 months (7-401 months), SAMHD1 expression in HRS cells significantly correlated with inferior freedom from progression (FFP) (P = 0·025), disease-specific survival (DSS) (P = 0·013) and overall survival (OS) (P = 0·01). Importantly, in multivariate models together with disease stage, histology subtype and type of treatment as covariates, SAMHD1 expression retained an independent significant association with unfavourable FFP (P = 0·005) as well as DSS (P = 0·022) and OS (P = 0·018). These findings uncover the significance of a novel, adverse prognostic factor in HL that may have therapeutic implications since SAMHD1 inhibitors are now available for clinical use.
Предметные рубрики MeSH
AdolescentAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBleomycinCell Line, TumorDacarbazineDisease-Free SurvivalDoxorubicinFemaleFollow-Up StudiesGene Expression Regulation, EnzymologicGene Expression Regulation, NeoplasticHodgkin DiseaseHumansLymph NodesMaleMiddle AgedNeoplasm StagingSAM Domain and HD Domain-Containing Protein 1Survival RateVinblastine